Medtronic Initiates Tax-Free Share Swap to Spin Off MiniMed Diabetes Unit

Medtronic (MDT) launched a voluntary exchange offer allowing shareholders to swap Medtronic ordinary shares for stock in its MiniMed diabetes unit, a transaction the company says is structured to be generally tax-free for U.S. federal income tax purposes. Under the offer, holders can tender Medtronic shares for MiniMed stock at an exchange ratio capped at 4.5939 MiniMed shares per Medtronic share, worth roughly $107.53 of MiniMed stock for every $100 of Medtronic shares tendered if that cap isn't triggered. Medtronic CEO Geoff Martha said the launch reflects confidence in MiniMed as an independent entity with what he called a rich innovation pipeline.

MiniMed has separately filed a Form S-4 registration statement covering the offer's mechanics. Sources describe the discount built into the deal differently: Medtronic's press release and wire recaps call it a 7% discount on the shares exchanged, while a Form 425 Q&A filed with the SEC instead values MiniMed stock at 93% of its average price over an October 5-7, 2026 reference period, which the filing frames as a 12% discount versus MiniMed's September 11, 2026 closing price. Neither source reconciles the two figures, so both are reported here rather than treating one as definitive.

The offer also carries a minimum participation threshold: at least 112,680,647 MiniMed shares, representing a minimum 80.1% split-off of the company, must be exchanged for the transaction to proceed. Reported figures for Medtronic's current MiniMed stake also diverge: Medtronic's press release and wire recaps put it at approximately 90% (about 252.8 million shares), while MiniMed's own S-4 announcement states Medtronic currently owns approximately 89.86% of the company. Medtronic is offering up to 225,361,295 MiniMed shares (80.1% of the company) in the exchange, with another 27,452,053 shares available if the offer is oversubscribed; MiniMed's release states that if fully subscribed, Medtronic would retain zero remaining equity stake in the business.

The pricing period for the final exchange ratio runs October 5-7, 2026, with the ratio to be announced by 9:00 a.m. ET on October 8 and the offer expiring October 9, 2026 if not extended. Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as dealer managers, with D.F. King & Co., Inc. as information agent. Investors could watch whether the offer clears its minimum-participation threshold and how the separated MiniMed business performs once it begins trading independently of Medtronic.